Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

Tae Won Yi^{1

2}, Michelle M Y Wong², Brendon L Neuen^{1

3}, Clare Arnott^{1

4

5

6}, Paul Poirier⁷, Jochen Seufert⁸, April Slee⁹, Wally Rapattoni¹⁰, Fernando G Ang¹⁰, David C Wheeler^{1

11}, Kenneth W Mahaffey¹², Vlado Perkovic^{1

3

4}, Adeera Levin²

Affiliations

¹ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
² Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
³ Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁴ Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
⁵ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
⁷ Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Québec, Canada.
⁸ Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁹ New Arch Consulting, Seattle, Washington, USA.
¹⁰ Janssen, Inc., Toronto, Ontario, Canada.
¹¹ Centre for Nephrology, University College London, London, UK.
¹² Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Tae Won Yi et al. Diabetes Obes Metab. 2023 Jul.

. 2023 Jul;25(7):2043-2047.

doi: 10.1111/dom.15065. Epub 2023 Apr 24.

¹ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
² Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
³ Royal North Shore Hospital, Sydney, New South Wales, Australia.
⁴ Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
⁵ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
⁶ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
⁷ Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Quebec City, Québec, Canada.
⁸ Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁹ New Arch Consulting, Seattle, Washington, USA.
¹⁰ Janssen, Inc., Toronto, Ontario, Canada.
¹¹ Centre for Nephrology, University College London, London, UK.
¹² Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

No abstract available

Keywords: SGLT2 inhibitor; canagliflozin; cardiovascular disease; type 2 diabetes.

References

1. Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119.
1. Nowakowska M, Zghebi SS, Ashcroft DM, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019;17(1):145.
1. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47(5):921-929.
1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
1. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.